Anthony F Shields MD PhD

Oncology•Detroit, MI

Gastrointestinal Cancer

Associate Center Director, Karmanos Cancer Institute, Professor of Oncology, Wayne State University

Join to View Full Profile

4100 John R Street, HW04HOKarmanos Cancer InstituteDetroit, MI 48201
Phone+1 800-527-6266
Fax+1 313-576-8767

Education & Training

University of WashingtonFellowship, Hematology and Medical Oncology, 1981 - 1984
University of WashingtonResidency, Internal Medicine, 1979 - 1981
Massachusetts Institute of TechnologyPhD, Biology, 1973 - 1979
Harvard Medical SchoolClass of 1979

Certifications & Licensure

MI State Medical License 1995 - 2027
WA State Medical License 1980 - 2002
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Super Doctor SuperDoctors.com

Clinical Trials

FDG-PET/CT Scans in Patients With Stage IIIB or Stage IV NSCLC Undergoing Chemotherapy Start of enrollment: 2007 Mar 30
Terminated
Not Applicable
3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer
RECRUITING
NA
Laboratory-Treated T Cells After Second-Line Chemotherapy in Treating Patients With HER2/Neu-Negative Metastatic Breast Cancer Start of enrollment: 2010 Mar 08
Terminated
Phase 2
Monitor Response to Treatment in Neuroblastoma Using 3&Apos;-Deoxy-3&Apos;-Fluorothymidine- Positron Emission Tomography (FLT-PET) Start of enrollment: 2011 Feb 01
Unknown status
Not Applicable
Anti-CD3 x Anti-Erbitux® Armed Activated T Cells (Phase Ib) for Gastrointestinal (GI Cancer) Start of enrollment: 2011 Aug 17
Completed
Phase 1
Fosaprepitant Dimeglumine in Preventing Nausea and Vomiting in Patients With Gastrointestinal Cancer Receiving Combination Chemotherapy Start of enrollment: 2012 Jun 01
Completed
Not Applicable
Cabozantinib-S-Malate in Treating Patients With Hormone-Resistant Metastatic Prostate Cancer Start of enrollment: 2013 Mar 01
Completed
Not Applicable
A Study of LY2880070 in Participants With Advanced or Metastatic Cancer Start of enrollment: 2016 May 16
Recruiting
Phase 1, Phase 2
A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of HH2710 in Patient With Advanced Tumors Start of enrollment: 2020 Jan 07
TERMINATED
PHASE1, PHASE2
AMT-PET in Monitoring Telotristat Etiprate Treatment in Participants With MetastaticNeuroendocrine Neoplasm Start of enrollment: 2018 Jun 20
Recruiting
Phase 2
Roles: Contact, Principal Investigator
RPTR-147 in Patients With Selected Solid Tumors and Lymphomas Start of enrollment: 2018 Oct 24
Terminated
Phase 1
Roles: Contact
Dexamethasone Effects in Patients With Refractory Non-Small Cell Lung Cancer Using FLT Positron Emission Tomography Start of enrollment: 2016 Jun 01
Active, not recruiting
Not Applicable
Roles: Principal Investigator, Contact
Join now to see all

Publications & Presentations

PubMed

1 citations
Comprehensive characterization of MCL-1 in patients with colorectal cancer: Expression, molecular profiles, and outcomes.
Pooja Mittal, Francesca Battaglin, Yasmine Baca, Joanne Xiu, Alex Farrell
International Journal of Cancer. 2025-04-15
Distinct Molecular and Clinical Features of Specific Variants of KRAS Codon 12 in Pancreatic Adenocarcinoma.
Bach Ardalan, Aaron Ciner, Yasmine Baca, Andrew Hinton, Sourat Darabi
Clinical Cancer Research. 2025-03-17
The association of physical activity with survival in colon cancer versus a matched general population: Data from Cancer and Leukemia Group B 89803 and 80702 (Alliance).
Justin C Brown, Chao Ma, Qian Shi, Leonard B Saltz, Anthony F Shields
Cancer. 2025-03-01

Press Mentions

Karmanos Cancer Institute Physicians Begin Prescribing New FDA-Approved Radiofrequency Electromagnetic Device to Treat Advanced Liver CancerDecember 18th, 2024
Karmanos Cancer Institute Receives $630,000 CATCH-UP Grant to Recruit Minority and Rural Patients to Clinical TrialsAugust 25th, 2020
OncLive® Presents State of the Science Summit™ on Gastrointestinal MalignanciesApril 23rd, 2019
Join now to see all

Grant Support

National Clinical Trials Network (NCTN) - Lead Academic Participating Site (LAPS)WAYNE STATE UNIVERSITY2019–2026
Imaging Cellular Stress And Treatment Response Using Positron Emission TomographyNational Cancer Institute2010–2012
Develpmental TherapeuticsNational Cancer Institute2005–2009
Labeled Thymidine -- Development As A PET Imaging AgentNational Cancer Institute2004–2008
Labeled Thymidine-Development As A PET Imaging AgentNational Cancer Institute2005–2006
Midcareer Investigator AwardNational Cancer Institute1999–2003
Labeled Thymidine--Development As A PET Imaging AgentNational Cancer Institute1997–2003
Developmental TherapeuticsNational Cancer Institute2001–2002
PET Imaging Of Drug Kinetics And PathwaysNational Cancer Institute1999–2002
Metabolic Measurement In Lymphoma Treated With ChemotherapyNational Cancer Institute1996–1997
Labeled Thymidine--Development As A PET Imaging AgentNational Cancer Institute1988–1994
Labeled Thymidine: Development As A PET Imaging AgentNational Cancer Institute1987–1993
Labeled Thymidine--Development As A PET Imaging AgentNational Cancer Institute1985–1987